2. Peptides
  3. Peptide and Derivatives
  4. Peptides for Drug Delivery
  5. Peptide Conjugates

Peptide Conjugates

Custom Peptide Synthesis

Peptide Conjugates (64):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106244A
    DOTATATE acetate 177943-89-4 99.82%
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-106244
    DOTATATE 177943-88-3 99.88%
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-153549
    Pentixafor 1341207-62-2 99.20%
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-106033
    Edotreotide 204318-14-9 98.15%
    Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer. Edotreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Edotreotide
  • HY-P4073
    ANG1005 1075214-55-9 98.83%
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
    ANG1005
  • HY-164725
    FAPI-mFS 3023869-94-2 99.78%
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu. FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-P10761
    DPI-4452 2941391-49-5
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models. DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DPI-4452
  • HY-P10239A
    Tyr3-Octreotate acetate 99.76%
    Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Tyr3-Octreotate acetate
  • HY-P5126
    DOTA-LM3 1192362-32-5 98.22%
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3
  • HY-P5128
    DOTA-JR11 1039726-31-2 98.81%
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research. DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-JR11
  • HY-P5018
    NOTA-AE105 1820563-84-5 98.91%
    NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by 64Cu and 68Ga. 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation. NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-AE105
  • HY-P10131
    3BP-3940 2803421-14-7 99.96%
    3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment. 3BP-3940 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    3BP-3940
  • HY-P5126A
    DOTA-LM3 TFA 99.30%
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3 TFA
  • HY-153550
    PSMA-1007 2226894-58-0 99.79%
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-1007
  • HY-P5362
    NODAGA-LM3 99.33%
    NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NODAGA-LM3
  • HY-P5292A
    HYNIC-iPSMA TFA 2375849-11-7 99.28%
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity. HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P5362A
    NODAGA-LM3 TFA
    NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NODAGA-LM3 TFA
  • HY-P2218
    Anditixafortide 1821136-83-7
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Anditixafortide
  • HY-D2363
    DOTA.SA.FAPi TFA 99.26%
    DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer. DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA.SA.FAPi TFA
  • HY-P10273A
    DOTA-Octreotide TFA 99.30%
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-Octreotide TFA